Skip to main content
Category

Insights

Living Our Mission at the Lab Bench

By Insights

The mission of CND Life Sciences—to advance the care of patients who face the potential diagnosis of a neurodegenerative disease—is continually being fulfilled one test at a time in our CLIA-certified and CAP-accredited lab at our global headquarters at the Pima Center in Scottsdale, Arizona.

Read More

Using Cutaneous Synuclein Biosignatures to Distinguish Parkinson’s Disease From Multiple System Atrophy

By Insights

A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders, Christopher Gibbons and Roy Freeman (and other academic colleagues), presented the first-ever data suggesting the possibility that measurable pathological markers in the skin can reveal distinct biological characteristics to help separate one type of synucleinopathy from another.

Read More